# OnCo record ascent (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ascent/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ascent", "NCT02574455" ;
  schema:name "ASCENT"@en ;
  schema:description "The trial that proved a TROP2 ADC could nearly double survival in heavily pretreated triple-negative breast cancer."@en ;
  schema:url <https://onco.cc/trials/ascent/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02574455>, <https://doi.org/10.1056/NEJMoa2028485>, <https://doi.org/10.1038/s41523-024-00635-5>, <https://www.nice.org.uk/guidance/ta819> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2017-11-07" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/trop2/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/> ;
  onco:companies <https://onco.cc/companies/gilead/> ;
  onco:trials <https://onco.cc/trials/ascent-03/>, <https://onco.cc/trials/ascent-04/>, <https://onco.cc/trials/keynote-119/> ;
  onco:people <https://onco.cc/people/aditya-bardia/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-ascent-nejm-2021/> .